# Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

> **NCT04068896** · PHASE1,PHASE2 · COMPLETED · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 89 (actual)

## Conditions studied

- Pancreatic Cancer
- Metastatic Castration-resistant Prostate Cancer
- Bladder Cancer
- Melanoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Esophageal Cancer
- Ovarian Cancer
- Head Neck Squamous Cell Carcinoma
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** NGM120 30mg
- **BIOLOGICAL:** NGM120 100mg
- **BIOLOGICAL:** NGM120 30mg with Gemcitabine and Abraxane
- **BIOLOGICAL:** NGM120 100mg with Gemcitabine and Abraxane
- **BIOLOGICAL:** NGM120 100mg Q3W
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04068896
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2023-09-21
- **Final completion:** 2024-01-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04068896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04068896, "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04068896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*